跳至主要内容
临床试验/NCT00604994
NCT00604994已完成不适用

Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer

Queensland Centre for Gynaecological Cancer6 个研究点 分布在 1 个国家目标入组 761 人开始时间: 2008年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
761
试验地点
6
主要终点
Time of onset of lymphoedema after gynaecological cancer treatment.

研究概览

简要总结

This project will conduct a prospective, longitudinal, observational cohort study to assess the onset and incidence of lymphoedema, as well as investigate factors associated with its development among women newly diagnosed with gynaecological cancers in 2008 to 2011.

详细描述

Pathological swelling of the lower limbs (lymphoedema) is widely accepted to be a common consequence of treatment for gynaecological cancer. It is both a serious and debilitating complication, associated with significant morbidity, which impacts physically and emotionally on otherwise healthy women. Lymphoedema can also affect patients' ability to earn an income, especially if their work requires prolonged periods of standing or walking.

The causes of lymphoedema are largely unknown with clinical data scarce regarding its onset time and incidence after gynaecological cancer treatment.

The following hypotheses will be tested to address the aims of the project:

  1. At least 20% of patients will develop lower-limb lymphoedema following gynaecological cancer treatment.
  2. Patient's age, as well as their body mass index (BMI), area of residence, degree of physical exercise, type of disease (uterine, cervical, ovarian, vulval/vaginal cancer; benign disease), mode of treatment (extent of lymph node dissection, radiotherapy, chemoradiation) and delay in wound healing are independent risk factors for lower-limb lymphoedema.
  3. Patients who develop lymphoedema after gynaecological cancer treatment, will experience increased pain, lower quality of life (including worse body-image), and decreased sexual & financial well-being, compared to those who do not develop lymphoedema.
  4. There will be at least 10% difference in the incidence of lower-limb lymphoedema between patients treated for gynaecological cancer compared to benign diseases.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients scheduled for surgery of benign or malignant gynaecological diseases as determined jointly by the surgeon and the patient.
  • Non-pregnant female patients.
  • Over 18 years of age at time of surgery.
  • Patients who understand the conditions of the study and are willing to participate for the length of the prescribed term of follow-up.
  • Patients who are capable of, and have given, informed consent to their participation in the study.

排除标准

  • Patients with a pacemaker.
  • Allergies against adhesive electrodes and extensive internal metal plates are ineligible for BIS measurement.

结局指标

主要结局

Time of onset of lymphoedema after gynaecological cancer treatment.

时间窗: 2 years

Incidence of lymphoedema after gynaecological cancer treatment.

时间窗: 2 years

Point prevalence of lymphoedema after gynaecological cancer treatment.

时间窗: 2 years

Severity of lymphoedema after gynaecological cancer treatment.

时间窗: 2 years

次要结局

  • Prevalence of key risk factors of post-treatment lymphoedema among patients with gynaecological cancer.(2 years)
  • Impact of risk factors on development of lymphoedema.(2 years)
  • Lymphoedema development in patients treated for gynaecological cancer compared to patients with benign disease.(2 years)

研究者

发起方
Queensland Centre for Gynaecological Cancer
申办方类型
Other Gov
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验